Annual report pursuant to Section 13 and 15(d)

Licenses Acquired (Tables)

v3.20.1
Licenses Acquired (Tables)
 12 Months Ended
Dec. 31, 2019
Licenses Acquired  
Schedule of research and development-licenses

For the years ended December 31, 2019 and 2018, the Company’s research and development-licenses acquired are comprised of the following:

 

 

 

 

 

 

 

 

 

 

For the Years Ended December 31, 

($ in thousands)

    

2019

    

2018

 

 

 

  

 

 

  

Partner companies:

 

 

  

 

 

  

Aevitas

 

$

 —

 

$

 1

Avenue

 

 

1,000

 

 

 —

Baergic

 

 

3,290

 

 

 —

Caelum

 

 

 —

 

 

252

Cellvation

 

 

 —

 

 

 1

Checkpoint

 

 

 —

 

 

1,000

Helocyte

 

 

450

 

 

1,521

Mustang

 

 

1,350

 

 

1,275

Total

 

$

6,090

 

$

4,050

 

Schedule of research and development for licenses acquired

For the years ended December 31, 2019 and 2018 Mustang recorded the following expense in research and development – licenses acquired:

 

 

 

 

 

 

 

 

 

 

($ in thousands)

 

 

 

For the Years Ended December 31, 

Institution

 

Program

 

2019

    

2018

City of Hope

 

MB-102 (CD 123 CAR T for AML)

 

$

250

 

$

 —

Nationwide Children's Hospital

 

MB-108 (C134 Oncolytic Virus for GBM)

 

 

200

 

 

 —

City of Hope

 

MB-104 (CS1 CAR T for Multiple Myeloma and Light Chain Amyloidosis)

 

 

200

 

 

 —

City of Hope

 

MB-105 (PSCA CAR T for Prostate & Pancreatic Cancers)

 

 

200

 

 

 —

CSL Behring

 

MB-107 (XSCID)

 

 

200

 

 

 —

UCLA

 

MB-105 (PSCA CAR T for Prostate & Pancreatic Cancers)

 

 

300

 

 

 —

City of Hope

 

MB-103 (HER2 CAR T for GBM & Metastatic Breast Cancer to Brain)

 

 

 —

 

 

200

St. Jude

 

MB-107 (XSCID)

 

 

 —

 

 

1,000

City of Hope

 

Manufacturing License

 

 

 —

 

 

75

Total

 

 

 

$

1,350

 

$

1,275